Pexidartinib
Brand names: Turalio · Active ingredient: Pexidartinib Hydrochloride
In short: TURALIO is indicated for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery.
What is Pexidartinib used for?
TURALIO is indicated for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery.
âš Boxed warning (FDA's strongest warning)
TURALIO can cause serious and potentially fatal liver injury, including vanishing bile duct syndrome .
Monitor liver tests prior to initiation of TURALIO and at specified intervals during treatment. Withhold and dose reduce or permanently discontinue TURALIO based on severity of hepatotoxicity. Monitoring and prompt cessation of TURALIO may not eliminate the risk of serious and potentially fatal liver injury .
TURALIO is available only through a restricted program called the TURALIO Risk Evaluation and Mitigation Strategy (REMS) Program .
Pexidartinib dosage
The recommended dosage of TURALIO is 250 mg taken orally twice daily with a low-fat meal (approximately 11 to 14 grams of total fat) until disease progression or unacceptable toxicity . Taking TURALIO with a high-fat meal (approximately 55 to 65 grams of total fat) increases pexidartinib concentrations and may increase the risk of adverse reactions, including hepatotoxicity [see Warnings and Precautions (5.1, 5.4), Drug Interactions (7.2), Clinical Pharmacology (12.2, 12.3)].
Swallow TURALIO capsules whole. Do not open, break, or chew the capsules.
If a patient vomits or misses a dose of TURALIO, instruct the patient to take the next dose at its scheduled time.
The recommended dose reductions for adverse reactions are provided in Table 1.
Dose Reduction | Total Daily Dose | Administration of Total Daily Dose with Low-Fat Meal
First | 375 mg | 125 mg in the morning and 250 mg in the evening
Second | 250 mg | 125 mg twice daily
Permanently discontinue TURALIO in patients who are unable to tolerate 125 mg orally twice daily.
The recommended dosage modifications for adverse reactions are summarized in Table 2.
Adverse Reaction | Severity | TURALIO Dosage Modifications
ALT = alanine aminotransferase; ALP = alkaline phosphatase; AST = aspartate aminotransferase; DB = direct bilirubin; GGT = gamma-glutamyl transferase; TB = total bilirubin; ULN = upper limit of normal
Hepatotoxicity
Increased ALT and/or AST | Greater than 3 to 5 times ULN | Withhold and monitor liver tests weekly.
If AST and ALT are less than or equal to 3 times ULN within 4 weeks, resume at reduced dose.
If AST or ALT is not less than or equal to 3 times ULN in 4 weeks, permanently discontinue TURALIO.
Greater than 5 to 10 times ULN | Withhold and monitor liver tests twice weekly.
If AST and ALT are less than or equal to 3 times ULN within 4 weeks, resume at reduced dose.
If AST or ALT is not less than or equal to 3 times ULN in 4 weeks, permanently discontinue TURALIO.
Greater than 10 times ULN | Permanently discontinue TURALIO.
Monitor liver tests twice weekly until AST or ALT is less than or equal to 5 times ULN, then weekly until less than or equal to 3 times ULN.
Increased ALPConfirm ALP elevations as liver isozyme fraction. and GGT | ALP greater than 2 times ULN with GGT greater than 2 times ULN | Permanently discontinue TURALIO. Monitor liver tests twice weekly until ALP is less than or equal to 5 times ULN, then weekly until less than or equal to 2 times ULN.
Increased bilirubin | TB greater than ULN to less than 2 times ULN or DB greater than ULN and less than 1.5 times ULN | Withhold and monitor liver tests twice weekly.
If an alternate cause for increased bilirubin is confirmed and bilirubin is less than ULN within 4 weeks, resume at reduced dose. …
How to take Pexidartinib — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Medication Guide).
Hepatotoxicity
Advise patients of the risk of hepatotoxicity that could be fatal and that they will need to undergo monitoring for liver injury. Advise patients to immediately report any signs or symptoms of severe liver injury to their healthcare provider and that liver testing and prompt cessation of TURALIO may not eliminate the risk of severe or life-threatening liver injury .
TURALIO REMS Program
TURALIO is available only through a restricted program called TURALIO REMS Program and patients are required to be part of the patient registry .
TURALIO is available only from certified pharmacies participating in the program. Therefore, provide patients with the telephone number and website for information on how to obtain the product.
Embryo-Fetal Toxicity
Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to inform their healthcare provider of a known or suspected pregnancy . …
Warnings & precautions
Do not take this medicine if: None.
TURALIO can cause serious and potentially fatal liver injury and is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) .
Hepatotoxicity, including liver failure and life-threatening vanishing bile duct syndrome (VBDS), ductopenia, and symptomatic cholestasis (including severe pruritus) can occur in patients treated with TURALIO and can occur despite monitoring and prompt drug cessation. The mechanism of cholestatic hepatotoxicity is unknown and its occurrence cannot be predicted. It is unknown whether liver injury can also occur in the absence of increased transaminases.
Of the first 609 patients who received TURALIO under the REMS program, 32 (5.3%) developed a liver injury event of concern (LIEC), defined as any serious liver-related outcome or any liver abnormality that triggers drug discontinuation per the US Prescribing Information . These 32 patients developed liver toxicity within 71 days of the first dose of TURALIO; ten required hospitalization, and two developed VBDS. Sixteen of the 32 patients had not fully recovered at the time of the analysis, including 6 patients followed for at least 6 months after discontinuation.
Among 768 patients who received TURALIO in clinical trials, there were two irreversible cases of cholestatic liver injury. One patient with advanced cancer and ongoing liver toxicity died and one patient with a confirmed case of VBDS required a liver transplant.
In ENLIVEN, 3 of 61 (5%) patients who received TURALIO developed signs of serious liver injury, defined as ALT or AST ≥3 × ULN with total bilirubin ≥2 × ULN. In these patients, peak ALT ranged from 6 to 9 × ULN, peak total bilirubin ranged from 2.5 to 15 × ULN, and alkaline phosphatase (ALP) was ≥2 × ULN. …
Pexidartinib side effects
The following clinically significant adverse reactions are described elsewhere in the labeling:
Hepatotoxicity .
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety of TURALIO 250 mg orally twice daily administered with a low-fat meal has been established based on adequate and well-controlled studies of TURALIO 400 mg orally twice daily administered on an empty stomach and additional pharmacokinetic data that indicate there is no clinically significant difference in the relative exposure between the two dosages .
The safety of TURALIO was evaluated in ENLIVEN . ENLIVEN excluded patients with ALT, AST, or total bilirubin >1.5 × ULN; and known active or chronic infection with hepatitis B or C virus, or human immunodeficiency virus. Patients received TURALIO without food at a dose of 400 mg in the morning and 600 mg in the evening orally for 2 weeks followed by 400 mg orally twice daily until disease progression or unacceptable toxicity. Seventy-nine percent of patients received TURALIO for 6 months or longer and 66% for greater than one year.
The median age of TURALIO-treated patients was 44 years (range: 22-75), 57% were females, and 85% were White.
Serious adverse reactions were reported in 13% of patients who received TURALIO. …
Drug interactions
TURALIO can cause hepatotoxicity. In patients with increased serum transaminases, total bilirubin, or direct bilirubin (>ULN) or active liver or biliary tract disease, avoid coadministration of TURALIO with other products known to cause hepatotoxicity .
Moderate or Strong CYP3A Inhibitors
Clinical Impact | Concomitant use of a moderate or strong CYP3A inhibitor may increase pexidartinib concentrations , which may increase the incidence and severity of adverse reactions of TURALIO.
Management | Reduce TURALIO dosage if concomitant use of moderate or strong CYP3A inhibitors, including grapefruit or grapefruit juice, cannot be avoided .
Strong CYP3A Inducers
Clinical Impact | Concomitant use of a strong CYP3A inducer decreases pexidartinib concentrations , which may decrease the efficacy of TURALIO.
Management | Avoid concomitant use of strong CYP3A inducers, including St John's wort.
UGT Inhibitors
Clinical Impact | Concomitant use of a UGT inhibitor increases pexidartinib concentrations , which may increase the incidence and severity of adverse reactions of TURALIO.
Management | Reduce TURALIO dosage if concomitant use of UGT inhibitors cannot be avoided . …
About this medicine
Pexidartinib is a kinase inhibitor. The chemical name of pexidartinib hydrochloride is 5-[(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-N-{[6-(trifluoromethyl)pyridin-3-yl]methyl}pyridin-2-amine monohydrochloride. Pexidartinib hydrochloride is an off-white to white solid. The molecular formula for pexidartinib hydrochloride is C20H15ClF3N5∙HCl. The molecular weight is 454.28 for the hydrochloride salt and 417.81 for the free base. The chemical structure is:
The solubility of pexidartinib hydrochloride in aqueous solutions decreases with increasing pH. The pKa1 and pKa2 were determined to be 2.6 and 5.4 respectively for the conjugate acids. Pexidartinib hydrochloride is soluble in methanol, slightly soluble in water and ethanol, and practically insoluble in heptane.
TURALIO (pexidartinib) capsules are for oral use. Each capsule contains 125 mg pexidartinib which is equivalent to 135.9 mg pexidartinib hydrochloride. The capsule contains the following inactive ingredients: poloxamer 407, mannitol, crospovidone, and magnesium stearate. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 7b0ec4bf-b2ac-49ee-96af-7740ad3f2e16. Read the full official label on DailyMed.
Related medicines
Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate